Shëndeti

A new Alzheimer's drug appears to slow the progression of the disease by a third

A new Alzheimer's drug appears to slow the progression of the disease by a

The decades-long battle to find treatments that reverse Alzheimer's disease is changing.

A new drug has been shown to slow the effects of the disease.

Medical experts say donanemab slows Alzheimer's by about a third.

The test was carried out by the pharmaceutical company Eli Lilly on 1,734 people in the earliest stages of the disease and is the second drug in less than a year that has been shown to slow the disease.

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35 percent less decline in thinking skills, Lilly announced in a statement.

The drug is designed to clear a sticky protein called beta-amyloid that builds up in the brain plaques that are a hallmark of Alzheimer's.

The preliminary results of the study have not been verified by external experts. Indianapolis-based Eli Lilly plans to release more details later in the summer.